Recombinant Anti-IGF1 antibody [EPR5099] (ab134140)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR5099] to IGF1
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-IGF1 antibody [EPR5099]
See all IGF1 primary antibodies -
Description
Rabbit monoclonal [EPR5099] to IGF1 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human IGF1 aa 100-200. The exact sequence is proprietary.
-
Positive control
- IGF1 recombinant protein
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20ºC. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR5099 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab134140 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/20000. Predicted molecular weight: 22 kDa.
|
Notes |
---|
WB
1/20000. Predicted molecular weight: 22 kDa. |
Target
-
Function
The insulin-like growth factors, isolated from plasma, are structurally and functionally related to insulin but have a much higher growth-promoting activity. May be a physiological regulator of [1-14C]-2-deoxy-D-glucose (2DG) transport and glycogen synthesis in osteoblasts. Stimulates glucose transport in rat bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin, not only regarding glycogen and DNA synthesis but also with regard to enhancing glucose uptake. -
Involvement in disease
Defects in IGF1 are the cause of insulin-like growth factor I deficiency (IGF1 deficiency) [MIM:608747]. IGF1 deficiency is an autosomal recessive disorder characterized by growth retardation, sensorineural deafness and mental retardation. -
Sequence similarities
Belongs to the insulin family. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 3479 Human
- Omim: 147440 Human
- SwissProt: P01343 Human
- SwissProt: P05019 Human
- Unigene: 160562 Human
-
Form
There are 2 isoforms produced by alternative splicing. Isoform 1 also known as: IGF-IB; Isoform 2 also known as: IGF-IA. -
Alternative names
- IBP1 antibody
- IGF I antibody
- IGF IA antibody
see all
Images
-
Anti-IGF1 antibody [EPR5099] (ab134140) at 1/20000 dilution (purified) + Human IGF-1 recombinant protein at 10 µg
Secondary
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 22 kDa
Observed band size: 10 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
-
Anti-IGF1 antibody [EPR5099] (ab134140) at 1/10000 dilution (unpurified) + IGF1 recombinant protein at 0.005 µg
Secondary
Goat Anti-rabbit HRP at 1/2000 dilution
Predicted band size: 22 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
References (2)
ab134140 has been referenced in 2 publications.
- Yang Y et al. Network Pharmacology and Molecular Docking-Based Mechanism Study to Reveal the Protective Effect of Salvianolic Acid C in a Rat Model of Ischemic Stroke. Front Pharmacol 12:799448 (2021). PubMed: 35153756
- O'Connor DM et al. Lot-to-Lot Variation in Adeno-Associated Virus Serotype 9 (AAV9) Preparations. Hum Gene Ther Methods 30:214-225 (2019). PubMed: 31752530